Commodore Capital LP Nuvalent, Inc. Transaction History
Commodore Capital LP
- $998 Million
- Q4 2024
A detailed history of Commodore Capital LP transactions in Nuvalent, Inc. stock. As of the latest transaction made, Commodore Capital LP holds 1,621,600 shares of NUVL stock, worth $126 Million. This represents 12.71% of its overall portfolio holdings.
Number of Shares
1,621,600
Previous 940,000
72.51%
Holding current value
$126 Million
Previous $96.2 Million
32.0%
% of portfolio
12.71%
Previous 8.17%
Shares
8 transactions
Others Institutions Holding NUVL
# of Institutions
234Shares Held
62.6MCall Options Held
834KPut Options Held
653K-
Deerfield Management Company, L.P. (Series C) New York, NY18MShares$1.4 Billion34.87% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5.36MShares$418 Million16.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.5MShares$351 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$236 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.62MShares$204 Million6.84% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $3.35B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...